New research overturns 40 years of heart treatment practice. The REBOOT trial, published in The New England Journal of Medicine and European Heart Journal, found beta-blockers offer no survival benefit for heart attack patients with normal heart function—and may harm women. Women on these drugs had up to 90% higher death risk, likely due to metabolic and physiological differences. Experts now call for personalized, root-cause prevention over outdated, one-size-fits-all prescriptions.
BETA-BLOCKERS increase women’s risk of death and cardiovascular events, according to new study
